Research Progress of Long Non-Coding RNA in Tumor Drug Resistance: A New Paradigm

References

• Chen Y, Zhang L, Li F, et al. Combination of chemotherapy and photodynamic therapy with oxygen self-supply in the form of mutual assistance for cancer therapy. Int J Nanomed. 2021;16:3679–3694. doi:10.2147/ijn.S298146
   PubMed Web of Science ®Google Scholar
• Nussinov R, Tsai CJ, Jang H. Anticancer drug resistance: an update and perspective. Drug Resist Updates. 2021;59:100796. doi:10.1016/j.drup.2021.100796
   PubMed Web of Science ®Google Scholar
• Nojima T, Proudfoot NJ. Mechanisms of lncRNA biogenesis as revealed by nascent transcriptomics. Nat Rev Mol Cell Biol. 2022;23(6):389–406. doi:10.1038/s41580-021-00447-6
   PubMed Web of Science ®Google Scholar
• Sánchez-Marín D, Trujano-Camacho S, Pérez-Plasencia C, De León DC, Campos-Parra AD. LncRNAs driving feedback loops to boost drug resistance: sinuous pathways in cancer. Cancer Lett. 2022;543:215763. doi:10.1016/j.canlet.2022.215763
   PubMed Web of Science ®Google Scholar
• Cao W, Chen HD, Yu YW, Li N, Chen WQ. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J. 2021;134(7):783–791. doi:10.1097/cm9.0000000000001474
   PubMed Web of Science ®Google Scholar
• Bridges MC, Daulagala AC, Kourtidis A. LNCcation: lncRNA localization and function. J Cell Biol. 2021;220(2). doi:10.1083/jcb.202009045
   PubMed Web of Science ®Google Scholar
• Ali T, Grote P. Beyond the RNA-dependent function of LncRNA genes. eLife. 2020;9. doi:10.7554/eLife.60583
   Web of Science ®Google Scholar
• Irwin AB, Bahabry R, Lubin FD. A putative role for lncRNAs in epigenetic regulation of memory. Neurochem Int. 2021;150:105184. doi:10.1016/j.neuint.2021.105184
   PubMed Web of Science ®Google Scholar
• Cai B, Song XQ, Cai JP, Zhang S. HOTAIR: a cancer-related long non-coding RNA. Neoplasma. 2014;61(4):379–391. doi:10.4149/neo_2014_075
   PubMed Web of Science ®Google Scholar
• Acosta-Baena N, Tejada-Moreno JA, Arcos-Burgos M, Villegas-Lanau CA. CTBP1 and CTBP2 mutations underpinning neurological disorders: a systematic review. Neurogenetics. 2022;23(4):231–240. doi:10.1007/s10048-022-00700-w
   PubMed Web of Science ®Google Scholar
• Herman AB, Tsitsipatis D, Gorospe M. Integrated lncRNA function upon genomic and epigenomic regulation. Molecular Cell. 2022;82(12):2252–2266. doi:10.1016/j.molcel.2022.05.027
   PubMed Web of Science ®Google Scholar
• Dittmer J. Biological effects and regulation of IGFBP5 in breast cancer. Front Endocrinol. 2022;13:983793. doi:10.3389/fendo.2022.983793
   PubMed Web of Science ®Google Scholar
• Zhang X, Wang W, Zhu W, et al. Mechanisms and functions of long non-coding RNAs at multiple regulatory levels. Int J Mol Sci. 2019;20(22). doi:10.3390/ijms20225573
   Web of Science ®Google Scholar
• Abbastabar M, Sarfi M, Golestani A, Khalili E. lncRNA involvement in hepatocellular carcinoma metastasis and prognosis. EXCLI J. 2018;17:900–913. doi:10.17179/excli2018-1541
   PubMed Web of Science ®Google Scholar
• Yao Z, Zhang Y, Xu D, et al. Research progress on long non-coding RNA and radiotherapy. Med Sci Monit. 2019;25:5757–5770. doi:10.12659/msm.915647
   PubMed Web of Science ®Google Scholar
• Chen Y, Li Z, Chen X, Zhang S. Long non-coding RNAs: from disease code to drug role. Acta pharmaceutica Sinica B. 2021;11(2):340–354. doi:10.1016/j.apsb.2020.10.001
   PubMed Web of Science ®Google Scholar
• Singh D, Assaraf YG, Gacche RN. Long non-coding RNA mediated drug resistance in breast cancer. Drug Resist Updates. 2022;63:100851. doi:10.1016/j.drup.2022.100851
   PubMed Web of Science ®Google Scholar
• Al-Rugeebah A, Alanazi M, Parine NR. MEG3: an oncogenic long non-coding RNA in different cancers. Pathol Oncol Res. 2019;25(3):859–874. doi:10.1007/s12253-019-00614-3
   PubMed Web of Science ®Google Scholar
• Li W, Li Y, Zhang H, et al. HOTAIR promotes gefitinib resistance through modification of EZH2 and silencing p16 and p21 in non-small cell lung cancer. J Cancer. 2021;12(18):5562–5572. doi:10.7150/jca.56093
   PubMed Web of Science ®Google Scholar
• Ying Z, Wenjing S, Jing B, Songbin F, Kexian D. Advances in long non-coding RNA regulating drug resistance of cancer. Gene. 2023;887:147726. doi:10.1016/j.gene.2023.147726
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhao F, Tan F, et al. HNF1A-AS1: a tumor-associated long non-coding RNA. Curr Pharm Des. 2022;28(21):1720–1729. doi:10.2174/1381612828666220520113846
   PubMed Web of Science ®Google Scholar
• Liu B, Wu S, Ma J, et al. lncRNA GAS5 reverses EMT and tumor stem cell-mediated gemcitabine resistance and metastasis by targeting miR-221/SOCS3 in pancreatic cancer. Mol Ther Nucleic Acids. 2018;13:472–482. doi:10.1016/j.omtn.2018.09.026
   PubMedGoogle Scholar
• Mariani A, Zaanan A, Glehen O, Karoui M. Outcomes of a Phase II Study of Intraperitoneal Paclitaxel Plus Systemic Capecitabine and Oxaliplatin (XELOX) for gastric cancer with peritoneal metastases. Ann Surg Oncol. 2023;30(2):816–817. doi:10.1245/s10434-022-12837-x
   PubMed Web of Science ®Google Scholar
• Hang Q, Sun R, Jiang C, Li Y. Notch 1 promotes cisplatin-resistant gastric cancer formation by upregulating lncRNA AK022798 expression. Anti-Cancer Drugs. 2015;26(6):632–640. doi:10.1097/cad.0000000000000227
   PubMed Web of Science ®Google Scholar
• Fang Q, Chen X, Zhi X. Long non-coding RNA (LncRNA) Urothelial Carcinoma Associated 1 (UCA1) increases multi-drug resistance of gastric cancer via downregulating miR-27b. Med Sci Monit. 2016;22:3506–3513. doi:10.12659/msm.900688
   PubMed Web of Science ®Google Scholar
• Li M, Zhang YY, Shang J, Xu YD. LncRNA SNHG5 promotes cisplatin resistance in gastric cancer via inhibiting cell apoptosis. Eur Rev Med Pharmacol Sci. 2019;23(10):4185–4191. doi:10.26355/eurrev_201905_17921
   PubMed Web of Science ®Google Scholar
• Wang J, Dong Z, Sheng Z, Cai Y. Hypoxia-induced PVT1 promotes lung cancer chemoresistance to cisplatin by autophagy via PVT1/miR-140-3p/ATG5 axis. Cell Death Discovery. 2022;8(1):104. doi:10.1038/s41420-022-00886-w
   PubMed Web of Science ®Google Scholar
• Cheng C, Qin Y, Zhi Q, Wang J, Qin C. Knockdown of long non-coding RNA HOTAIR inhibits cisplatin resistance of gastric cancer cells through inhibiting the PI3K/Akt and Wnt/β-catenin signaling pathways by up-regulating miR-34a. Int J Biol Macromol. 2018;107(Pt B):2620–2629. doi:10.1016/j.ijbiomac.2017.10.154
   PubMedGoogle Scholar
• Zhang C, Qian H, Liu K, Zhao W, Wang L. A feedback loop regulation of LINC01433 and YAP promotes malignant behavior in gastric cancer cells. Onco Targets Ther. 2019;12:7949–7962. doi:10.2147/ott.S222903
   PubMed Web of Science ®Google Scholar
• YiRen H, YingCong Y, Sunwu Y, et al. Long noncoding RNA MALAT1 regulates autophagy associated chemoresistance via miR-23b-3p sequestration in gastric cancer. Mol Cancer. 2017;16(1):174. doi:10.1186/s12943-017-0743-3
   PubMed Web of Science ®Google Scholar
• Zhan L, Su F, Li Q, et al. Phytochemicals targeting glycolysis in colorectal cancer therapy: effects and mechanisms of action. Front Pharmacol. 2023;14:1257450. doi:10.3389/fphar.2023.1257450
   PubMed Web of Science ®Google Scholar
• Li C, Zhang K, Gong Y, et al. Based on cuproptosis-related lncRNAs, a novel prognostic signature for colon adenocarcinoma prognosis, immunotherapy, and chemotherapy response. Front Pharmacol. 2023;14:1200054. doi:10.3389/fphar.2023.1200054
   PubMed Web of Science ®Google Scholar
• Lee H, Kim C, Ku JL, et al. A long non-coding RNA snaR contributes to 5-fluorouracil resistance in human colon cancer cells. Mol Cells. 2014;37(7):540–546. doi:10.14348/molcells.2014.0151
   PubMed Web of Science ®Google Scholar
• Wang M, Han D, Yuan Z, et al. Long non-coding RNA H19 confers 5-Fu resistance in colorectal cancer by promoting SIRT1-mediated autophagy. Cell Death Dis. 2018;9(12):1149. doi:10.1038/s41419-018-1187-4
   PubMed Web of Science ®Google Scholar
• Chen S, Bu D, Ma Y, et al. H19 overexpression induces resistance to 1,25(OH)2D3 by targeting VDR through miR-675-5p in colon cancer cells. Neoplasia. 2017;19(3):226–236. doi:10.1016/j.neo.2016.10.007
   PubMed Web of Science ®Google Scholar
• Wu KF, Liang WC, Feng L, et al. H19 mediates methotrexate resistance in colorectal cancer through activating Wnt/β-catenin pathway. Exp Cell Res. 2017;350(2):312–317. doi:10.1016/j.yexcr.2016.12.003
   PubMed Web of Science ®Google Scholar
• Eisa NH, Said E, Khodir AE, et al. Effect of diacerein on HOTAIR/IL-6/STAT3, Wnt/β-Catenin and TLR-4/NF-κB/TNF-α axes in colon carcinogenesis. Environ Toxicol Pharmacol. 2022;95:103943. doi:10.1016/j.etap.2022.103943
   PubMed Web of Science ®Google Scholar
• Karpov DS, Spirin PV, Zheltukhin AO, et al. LINC00973 induces proliferation arrest of drug-treated cancer cells by preventing p21 degradation. Int J Mol Sci. 2020;21(21):8322.
   PubMed Web of Science ®Google Scholar
• Lim B, Song J, Ibrahim NK, et al. A randomized Phase II Study of sequential eribulin versus paclitaxel followed by FAC/FEC as neoadjuvant therapy in patients with operable HER2-negative breast cancer. Oncologist. 2021;26(2):e230–e240. doi:10.1002/onco.13581
   PubMed Web of Science ®Google Scholar
• Xu Z, Zhao D, Zheng X, Huang B, Pan X, Xia X. Low concentrations of 17β-estradiol exacerbate tamoxifen resistance in breast cancer treatment through membrane estrogen receptor-mediated signaling pathways. Environ Toxicol. 2022;37(3):514–526. doi:10.1002/tox.23417
   PubMed Web of Science ®Google Scholar
• Lu PW, Li L, Wang F, Gu YT. Inhibitory role of large intergenic noncoding RNA-ROR on tamoxifen resistance in the endocrine therapy of breast cancer by regulating the PI3K/Akt/mTOR signaling pathway. J Cell Physiol. 2019;234(2):1904–1912. doi:10.1002/jcp.27066
   PubMed Web of Science ®Google Scholar
• Zhang M, Wu K, Zhang P, Qiu Y, Bai F, Chen H. HOTAIR facilitates endocrine resistance in breast cancer through ESR1/miR-130b-3p axis: comprehensive analysis of mRNA-miRNA-lncRNA network. Int J Gene Med. 2021;14:4653–4663. doi:10.2147/ijgm.S320998
   PubMed Web of Science ®Google Scholar
• Sun W, Xu X, Jiang Y, et al. Transcriptome analysis of luminal breast cancer reveals a role for LOL in tumor progression and tamoxifen resistance. Int J Can. 2019;145(3):842–856. doi:10.1002/ijc.32185
   PubMed Web of Science ®Google Scholar
• Han J, Qu H, Han M, et al. Retraction Note: MSC-induced lncRNA AGAP2-AS1 promotes stemness and trastuzumab resistance through regulating CPT1 expression and fatty acid oxidation in breast cancer. Oncogene. 2023;42(31):2415. doi:10.1038/s41388-023-02774-8
   PubMed Web of Science ®Google Scholar
• Qian XK, Qu HB, Zhang F, et al. Exosomal long noncoding RNA AGAP2-AS1 regulates trastuzumab resistance via inducing autophagy in breast cancer [Retraction]. Am J Cancer Res. 2023;13(2):712.
   PubMed Web of Science ®Google Scholar
• Wu J, Lin Z. Non-small cell lung cancer targeted therapy: drugs and mechanisms of drug resistance. Int J Mol Sci. 2022;23(23):15056.
   PubMed Web of Science ®Google Scholar
• Li K, Gong Q, Xiang XD, et al. HNRNPA2B1-mediated m(6)A modification of lncRNA MEG3 facilitates tumorigenesis and metastasis of non-small cell lung cancer by regulating miR-21-5p/PTEN axis. J Transl Med. 2023;21(1):382. doi:10.1186/s12967-023-04190-8
   PubMed Web of Science ®Google Scholar
• Shen Q, Wang H, Zhang L. TP63 functions as a tumor suppressor regulated by GAS5/miR-221-3p signaling axis in human non-small cell lung cancer cells. Cancer Manage Res. 2023;15:217–231. doi:10.2147/cmar.S387781
   PubMed Web of Science ®Google Scholar
• Reungwetwattana T, Cho BC, Lee KH, et al. Lazertinib versus gefitinib tyrosine kinase inhibitors in treatment-naíve patients with EGFR-mutated advanced NSCLC: analysis of the Asian Subpopulation in LASER301. J Thorac Oncol. 2023;18(10):1351–1361. doi:10.1016/j.jtho.2023.06.016
   PubMed Web of Science ®Google Scholar
• Braga EA, Fridman MV, Burdennyy AM, et al. Various LncRNA mechanisms in gene regulation involving miRNAs or RNA-binding proteins in non-small-cell lung cancer: main signaling pathways and networks. Int J Mol Sci. 2023;24(17):13617.
   PubMed Web of Science ®Google Scholar
• Fazaeli H, Sheikholeslami A, Ghasemian F, Amini E, Sheykhhasan M. The emerging role of LncRNA FENDRR in multiple cancers: a review. Curr Mol Med. 2023;23(7):606–629. doi:10.2174/1566524022666220509122505
   PubMed Web of Science ®Google Scholar
• Zhang Y, Liu Z, Li J, et al. Oncogenic pathways refine a new perspective on the classification of hepatocellular carcinoma. Cell Signalling. 2023;111:110890. doi:10.1016/j.cellsig.2023.110890
   PubMed Web of Science ®Google Scholar
• Jin W, Chen L, Cai X, et al. Long non-coding RNA TUC338 is functionally involved in sorafenib-sensitized hepatocarcinoma cells by targeting RASAL1. Oncol Rep. 2017;37(1):273–280. doi:10.3892/or.2016.5248
   PubMed Web of Science ®Google Scholar
• Cheng Z, Lei Z, Yang P, et al. Long non-coding RNA THOR promotes liver cancer stem cells expansion via β-catenin pathway. Gene. 2019;684:95–103. doi:10.1016/j.gene.2018.10.051
   PubMed Web of Science ®Google Scholar
• Shi Y, Yang X, Xue X, et al. HANR enhances autophagy-associated sorafenib resistance through miR-29b/ATG9A axis in hepatocellular carcinoma. Onco Targets Ther. 2020;13:2127–2137. doi:10.2147/ott.S229913
   PubMed Web of Science ®Google Scholar
• Niu Y, Tang G, Wu X, Wu C. LncRNA NEAT1 modulates sorafenib resistance in hepatocellular carcinoma through regulating the miR-149-5p/AKT1 axis. Saudi J Gastroenterol. 2020;26(4):194–203. doi:10.4103/sjg.SJG_4_20
   PubMed Web of Science ®Google Scholar
• Tsuchiya H, Shinonaga R, Sakaguchi H, Kitagawa Y, Yoshida K. NEAT1-SOD2 axis confers sorafenib and lenvatinib resistance by activating AKT in liver cancer cell lines. Curr Issues Mol Biol. 2023;45(2):1073–1085. doi:10.3390/cimb45020071
   PubMed Web of Science ®Google Scholar
• Huang H, Zhang S, Wen X, et al. Transcription factors and ncRNAs associated with CYP3A expression in human liver and small intestine assessed with weighted gene co-expression network analysis. Biomedicines. 2022;10(12):3061.
   PubMed Web of Science ®Google Scholar
• Yuan P, Cao W, Zang Q, Li G, Guo X, Fan J. The HIF-2α-MALAT1-miR-216b axis regulates multi-drug resistance of hepatocellular carcinoma cells via modulating autophagy. Biochem Biophys Res Commun. 2016;478(3):1067–1073. doi:10.1016/j.bbrc.2016.08.065
   PubMed Web of Science ®Google Scholar
• Xiong H, Ni Z, He J, et al. LncRNA HULC triggers autophagy via stabilizing Sirt1 and attenuates the chemosensitivity of HCC cells. Oncogene. 2017;36(25):3528–3540. doi:10.1038/onc.2016.521
   PubMed Web of Science ®Google Scholar
• More P, Ngaffo JAM, Goedtel-Armbrust U, et al. Transcriptional response to standard AML drugs identifies synergistic combinations. Int J Mol Sci. 2023;24(16):12926.
   PubMed Web of Science ®Google Scholar
• Chen L, Zhao H, Wang C, Hu N. TUG1 knockdown enhances Adriamycin cytotoxicity by inhibiting glycolysis in Adriamycin-resistant acute myeloid leukemia HL60/ADR cells. RSC Adv. 2019;9(19):10897–10904. doi:10.1039/c9ra00306a
   PubMed Web of Science ®Google Scholar
• Wen F, Cao YX, Luo ZY, Liao P, Lu ZW. LncRNA MALAT1 promotes cell proliferation and imatinib resistance by sponging miR-328 in chronic myelogenous leukemia. Biochem Biophys Res Commun. 2018;507(1–4):1–8. doi:10.1016/j.bbrc.2018.09.034
   PubMed Web of Science ®Google Scholar
• Li Z, Yang L, Liu X, Nie Z, Luo J. Long noncoding RNA MEG3 inhibits proliferation of chronic myeloid leukemia cells by sponging microRNA21. Biomed Pharmacothe. 2018;104:181–192. doi:10.1016/j.biopha.2018.05.047
   PubMed Web of Science ®Google Scholar
• Xiao Y, Jiao C, Lin Y, et al. lncRNA UCA1 contributes to imatinib resistance by acting as a ceRNA against miR-16 in chronic myeloid leukemia cells. DNA Cell Biol. 2017;36(1):18–25. doi:10.1089/dna.2016.3533
   PubMed Web of Science ®Google Scholar
• Peran I, Dakshanamurthy S, McCoy MD, et al. Cadherin 11 promotes immunosuppression and extracellular matrix deposition to support growth of pancreatic tumors and resistance to gemcitabine in mice. Gastroenterology. 2021;160(4):1359–1372.e1313. doi:10.1053/j.gastro.2020.11.044
   PubMed Web of Science ®Google Scholar
• Li Z, Zhao X, Zhou Y, et al. The long non-coding RNA HOTTIP promotes progression and gemcitabine resistance by regulating HOXA13 in pancreatic cancer. J Transl Med. 2015;13:84. doi:10.1186/s12967-015-0442-z
   PubMed Web of Science ®Google Scholar
• Peltier DC, Roberts A, Reddy P. LNCing RNA to immunity. Trends Immunol. 2022;43(6):478–495. doi:10.1016/j.it.2022.04.002
   PubMed Web of Science ®Google Scholar
• Li X, Zhang Y, Pei W, et al. LncRNA Dnmt3aos regulates Dnmt3a expression leading to aberrant DNA methylation in macrophage polarization. FASEB J. 2020;34(4):5077–5091. doi:10.1096/fj.201902379R
   PubMed Web of Science ®Google Scholar
• Mi X, Xu R, Hong S, Xu T, Zhang W, Liu M. M2 macrophage-derived exosomal lncRNA AFAP1-AS1 and MicroRNA-26a affect cell migration and metastasis in esophageal cancer. Mol Ther Nucleic Acids. 2020;22:779–790. doi:10.1016/j.omtn.2020.09.035
   PubMedGoogle Scholar
• Tu J, Wu F, Chen L, et al. Long non-coding RNA PCAT6 induces M2 polarization of macrophages in cholangiocarcinoma via modulating miR-326 and RhoA-ROCK signaling pathway. Front Oncol. 2020;10:605877. doi:10.3389/fonc.2020.605877
   PubMed Web of Science ®Google Scholar
• Yao X, Wang Q, Zeng P, et al. LncRNA HOTTIP from synovial fibroblast-derived exosomes: a novel molecular target for rheumatoid arthritis through the miR-1908-5p/STAT3 axis. Exp Cell Res. 2021;409(2):112943. doi:10.1016/j.yexcr.2021.112943
   PubMed Web of Science ®Google Scholar
• Zhu H, Tang JH, Zhang SM, et al. Long noncoding RNA LINC00963 promotes CDC5L-mediated malignant progression in gastric cancer. Onco Targets Ther. 2020;13:12999–13013. doi:10.2147/ott.S274708
   PubMed Web of Science ®Google Scholar
• Fang P, Xiang L, Chen W, et al. LncRNA GAS5 enhanced the killing effect of NK cell on liver cancer through regulating miR-544/RUNX3. Innate Immun. 2019;25(2):99–109. doi:10.1177/1753425919827632
   PubMed Web of Science ®Google Scholar
• Jafari L, Izadirad M, Vatanmakanian M, et al. IFNG-AS1 and MAF4 long non-coding RNAs are upregulated in acute leukemia patients who underwent bone marrow transplantation. Curr Res Transl Med. 2021;69(4):103307. doi:10.1016/j.retram.2021.103307
   PubMed Web of Science ®Google Scholar
• Gomez JA, Wapinski OL, Yang YW, et al. The NeST long ncRNA controls microbial susceptibility and epigenetic activation of the interferon-γ locus. Cell. 2013;152(4):743–754. doi:10.1016/j.cell.2013.01.015
   PubMed Web of Science ®Google Scholar
• Pei X, Wang X, Li H. LncRNA SNHG1 regulates the differentiation of Treg cells and affects the immune escape of breast cancer via regulating miR-448/IDO. Int J Biol Macromol. 2018;118(Pt A):24–30. doi:10.1016/j.ijbiomac.2018.06.033
   PubMed Web of Science ®Google Scholar
• Yao K, Wang Q, Jia J, Zhao H. A competing endogenous RNA network identifies novel mRNA, miRNA and lncRNA markers for the prognosis of diabetic pancreatic cancer. Tumour Biol. 2017;39(6):1010428317707882. doi:10.1177/1010428317707882
   Google Scholar
• Yan K, Fu Y, Zhu N, et al. Repression of lncRNA NEAT1 enhances the antitumor activity of CD8(+)T cells against hepatocellular carcinoma via regulating miR-155/Tim-3. Int J Biochem Cell Biol. 2019;110:1–8. doi:10.1016/j.biocel.2019.01.019
   PubMed Web of Science ®Google Scholar
• Morchikh M, Cribier A, Raffel R, et al. HEXIM1 and NEAT1 long non-coding RNA form a multi-subunit complex that regulates DNA-mediated innate immune response. Molecular Cell. 2017;67(3):387–399.e385. doi:10.1016/j.molcel.2017.06.020
   PubMed Web of Science ®Google Scholar
• Zhou WY, Zhang MM, Liu C, Kang Y, Wang JO, Yang XH. Long noncoding RNA LINC00473 drives the progression of pancreatic cancer via upregulating programmed death-ligand 1 by sponging microRNA-195-5p. J Cell Physiol. 2019;234(12):23176–23189. doi:10.1002/jcp.28884
   PubMed Web of Science ®Google Scholar
• Cassetta L, Pollard JW. Targeting macrophages: therapeutic approaches in cancer. Nat Rev Drug Discov. 2018;17(12):887–904. doi:10.1038/nrd.2018.169
   PubMed Web of Science ®Google Scholar
• Liu QP, Lin JY, An P, Chen YY, Luan X, Zhang H. LncRNAs in tumor microenvironment: the potential target for cancer treatment with natural compounds and chemical drugs. Biochem Pharmacol. 2021;193:114802. doi:10.1016/j.bcp.2021.114802
   PubMed Web of Science ®Google Scholar
• Huang D, Chen J, Yang L, et al. NKILA lncRNA promotes tumor immune evasion by sensitizing T cells to activation-induced cell death. Nat Immunol. 2018;19(10):1112–1125. doi:10.1038/s41590-018-0207-y
   PubMed Web of Science ®Google Scholar
• Chen T, Ren L, Liu X, et al. DNA nanotechnology for cancer diagnosis and therapy. Int J Mol Sci. 2018;19(6):1671.
   PubMed Web of Science ®Google Scholar
• Sarfi M, Abbastabar M, Khalili E. Long noncoding RNAs biomarker-based cancer assessment. J Cell Physiol. 2019;234(10):16971–16986. doi:10.1002/jcp.28417
   PubMed Web of Science ®Google Scholar
• Hessels D, Schalken JA. The use of PCA3 in the diagnosis of prostate cancer. Nat Rev Urol. 2009;6(5):255–261. doi:10.1038/nrurol.2009.40
   PubMed Web of Science ®Google Scholar
• Ghafouri-Fard S, Esmaeili M, Taheri M, Samsami M. Highly upregulated in liver cancer (HULC): an update on its role in carcinogenesis. J Cell Physiol. 2020;235(12):9071–9079. doi:10.1002/jcp.29765
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhou Y, Huang T, et al. The interplay of LncRNA-H19 and its binding partners in physiological process and gastric carcinogenesis. Int J Mol Sci. 2017;18(2):450.
   PubMed Web of Science ®Google Scholar
• Balakittnen J, Weeramange CE, Wallace DF, et al. Noncoding RNAs in oral cancer. Wiley Interdiscip Rev RNA. 2023;14(3):e1754. doi:10.1002/wrna.1754
   PubMed Web of Science ®Google Scholar
• Toden S, Zumwalt TJ, Goel A. Non-coding RNAs and potential therapeutic targeting in cancer. Biochim Biophys Acta Rev Cancer. 2021;1875(1):188491. doi:10.1016/j.bbcan.2020.188491
   PubMed Web of Science ®Google Scholar
• Ebrahimi N, Parkhideh S, Samizade S, et al. Crosstalk between lncRNAs in the apoptotic pathway and therapeutic targets in cancer. Cytokine Growth Factor Rev. 2022;65:61–74. doi:10.1016/j.cytogfr.2022.04.003
   PubMed Web of Science ®Google Scholar
• Winkle M, El-Daly SM, Fabbri M, Calin GA. Noncoding RNA therapeutics - challenges and potential solutions. Nat Rev Drug Discov. 2021;20(8):629–651. doi:10.1038/s41573-021-00219-z
   PubMed Web of Science ®Google Scholar
• Zhang Z, Gu M, Gu Z, Lou YR. Role of long non-coding RNA polymorphisms in cancer chemotherapeutic response. J Person Med. 2021;11(6):513.
   PubMed Web of Science ®Google Scholar
• Mineo M, Lyons SM, Zdioruk M, et al. Tumor interferon signaling is regulated by a lncRNA INCR1 transcribed from the PD-L1 Locus. Molecular Cell. 2020;78(6):1207–1223.e1208. doi:10.1016/j.molcel.2020.05.015
   PubMed Web of Science ®Google Scholar
• Johnson LR, Lee DY, Eacret JS, Ye D, June CH, Minn AJ. The immunostimulatory RNA RN7SL1 enables CAR-T cells to enhance autonomous and endogenous immune function. Cell. 2021;184(19):4981–4995.e4914. doi:10.1016/j.cell.2021.08.004
   PubMed Web of Science ®Google Scholar
• Han D, Fang Y, Guo Y, Hong W, Tu J, Wei W. The emerging role of long non-coding RNAs in tumor-associated macrophages. J Cancer. 2019;10(26):6738–6746. doi:10.7150/jca.35770
   PubMed Web of Science ®Google Scholar
• Lijuan Y, Yinhang W, Yangyanqiu W, Xiaohui H, Yunhai W, Shuwen H. Differences in T cell immune-related lncRNA and mRNA expression patterns between right- and left-sided colorectal cancers. Hum Immunol. 2021;82(12):950–959. doi:10.1016/j.humimm.2021.08.008
   PubMed Web of Science ®Google Scholar